268 related articles for article (PubMed ID: 21448091)
1. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
Jakovljević M
Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
[TBL] [Abstract][Full Text] [Related]
2. Addressing circadian rhythm disturbances in depressed patients.
Lam RW
J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
[TBL] [Abstract][Full Text] [Related]
3. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
4. [Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].
Sumegi A; Somoskovi C
Neuropsychopharmacol Hung; 2010 Dec; 12(4):469-75. PubMed ID: 21220792
[TBL] [Abstract][Full Text] [Related]
5. Restoring circadian rhythms: a new way to successfully manage depression.
Gorwood P
J Psychopharmacol; 2010 Aug; 24(2 Suppl):15-9. PubMed ID: 20663804
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
9. Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
Højgaard K; Christiansen SL; Bouzinova EV; Wiborg O
Psychopharmacology (Berl); 2018 Mar; 235(3):627-640. PubMed ID: 29151193
[TBL] [Abstract][Full Text] [Related]
10. [Depression as chronobiological illness].
Kálmán J; Kálmán S
Neuropsychopharmacol Hung; 2009 Jun; 11(2):69-81. PubMed ID: 19827314
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
[TBL] [Abstract][Full Text] [Related]
12. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
13. [Agomelatine].
Tessmer M
Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
[TBL] [Abstract][Full Text] [Related]
14. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
15. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
Quera-Salva MA; Lemoine P; Guilleminault C
Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
[TBL] [Abstract][Full Text] [Related]
16. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
17. The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
Lam RW
J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806
[TBL] [Abstract][Full Text] [Related]
18. The preclinical discovery and development of agomelatine for the treatment of depression.
Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
[TBL] [Abstract][Full Text] [Related]
19. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]